Next Article in Journal
Inhibition of Cysteine Proteases by 6,6′-Dihydroxythiobinupharidine (DTBN) from Nuphar lutea
Next Article in Special Issue
Promising Antimycobacterial Activities of Flavonoids against Mycobacterium sp. Drug Targets: A Comprehensive Review
Previous Article in Journal
Phenolics-Rich Extracts of Dietary Plants as Regulators of Fructose Uptake in Caco-2 Cells via GLUT5 Involvement
Previous Article in Special Issue
Riminophenazine Derivatives as Potential Antituberculosis Agents: Synthesis, Biological, and Electrochemical Evaluations
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 16
10.3390/molecules26164742
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis

by
Marc Montana
1,2,
Vincent Montero
1,
Omar Khoumeri
1 and
Patrice Vanelle
1,3,*
1
Aix Marseille Univ, CNRS, ICR, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, 13005 Marseille, France
2
Assistance Publique-Hôpitaux de Marseille (AP-HM), Oncopharma, 13015 Marseille, France
3
Assistance Publique-Hôpitaux de Marseille (AP-HM), Service Central de la Qualité et de l’Information Pharmaceutiques (SCQIP), 13005 Marseille, France
*
Author to whom correspondence should be addressed.
Molecules 2021, 26(16), 4742; https://doi.org/10.3390/molecules26164742
Submission received: 11 June 2021 / Revised: 16 July 2021 / Accepted: 3 August 2021 / Published: 5 August 2021
(This article belongs to the Special Issue Antitubercular Drug Discovery: Implication and Challenges)
Browse Figures
Versions Notes

Abstract

:
Background. The past decades have seen numerous efforts to develop new antitubercular agents. Currently, the available regimens are lengthy, only partially effective, and associated with high rates of adverse events. The challenge is therefore to develop new agents with faster and more efficient action. The versatile quinoxaline ring possesses a broad spectrum of pharmacological activities, ensuring considerable attention to it in the field of medicinal chemistry. Objectives. In continuation of our program on the pharmacological activity of quinoxaline derivatives, this review focuses on potential antimycobacterial activity of recent quinoxaline derivatives and discusses their structure—activity relationship for designing new analogs with improved activity. Methods. The review compiles recent studies published between January 2011 and April 2021. Results. The final total of 23 studies were examined. Conclusions. Data from studies of quinoxaline and quinoxaline 1,4-di-N-oxide derivatives highlight that specific derivatives show encouraging perspectives in the treatment of Mycobacterium tuberculosis and the recent growing interest for these scaffolds. These interesting results warrant further investigation, which may allow identification of novel antitubercular candidates based on this scaffold.

1. Introduction

In 2020, the World Health Organization estimated that about 10 million people (range: 8.9–11.0 million) contracted tuberculosis (TB) in 2019, which was responsible for 1.4 million deaths [1]. Treatment of drug-susceptible active tuberculosis consists of a standard 6-month regimen of four antimicrobials (usually isoniazid, rifampin, pyrazinamide, and ethambutol) [2,3]. However, these regimens are lengthy, only partially effective, and associated with high rates of adverse events. The challenge is therefore to develop new agents with faster and more efficient action.
Nitrogen-containing heterocycles are of particular interest for the development of new drugs or novel potential lead molecules [4,5,6,7,8]. Quinoxaline, formed by the fusion of two aromatic rings, benzene and pyrazine, is one of the heterocycles receiving the most attention.
The versatile quinoxaline ring possesses a broad spectrum of pharmacological activities (antiviral [9], anticancer [10], antileishmanial [11]), ensuring considerable attention to it in the field of medicinal chemistry [12]. In addition, as quinoxaline is also a part of well-known wide-spectrum antibiotics echinomycin, levomycin, and actinoleutin, quinoxaline derivatives are expected to have antimycobacterial activity. One of them, clofazimine, initially known as B663, is currently under intensive clinical investigation for the treatment of drug-resistant TB to assess the compound’s treatment outcomes with multidrug-resistant and extensively drug-resistant TB (Figure 1).
Some quinoxaline-1,4-di-N-oxide derivatives have also shown excellent antimicrobial activities against Mycobacterium tuberculosis [13,14,15], indicating the great interest of these types of structure for the development of new structural classes of anti-TB drugs. The oxidation of nitrogen in a quinoxaline ring has a pronounced effect on antimycobacterial activity [16]. In addition, quinoxaline 1,4-di-N-oxides are species that suffer a bioreductive process under the hypoxic conditions [17] found in tuberculous granulomas, where nonreplicating persistent forms of Mycobacterium tuberculosis bacilli can survive, leading to the need for long treatments and the risk of treatment resistance [13]. In continuation of our program on the pharmacological activity of quinoxaline derivatives, we decided to focus on the development of new quinoxalines and quinoxaline 1,4-di-N-oxide derivatives as antitubercular drugs. This review compiles studies published between 2011 and 2021 and discusses the potential antimycobacterial activity of recent quinoxaline derivatives.

2. Methods

2.1. Data Sources and Searches

The research was conducted using three databases: MEDLINE/PubMed, Web of Science, and Science Direct Elsevier (Table 1).

2.2. Study Selection

The review was performed by two independent reviewers as described by PRISMA [18]. Eligibility criteria were predetermined by the authors (Table 2).
In the first step, duplicates were eliminated. Then, articles’ titles and abstracts were evaluated according to the inclusion criteria. The authors read each selected full text and eliminated articles fitting the exclusion criteria. During this stage, the references of the relevant articles were examined to identify additional studies not retrieved in computerized databases.

3. Results

The database search identified 148 records; 27 repeated files were discarded, leaving 121 articles.
After the evaluation phase (title/abstract) and full-text reading, 98 records were excluded. The final total of 23 studies were included in this review. No other paper was added from the reference lists of the identified studies.
During the 2011–2015 and the 2016–2021 periods, six articles (two concerning 1,4-di-N-oxide-quinoxaline derivatives and four concerning quinoxaline derivatives) and 17 articles (six concerning 1,4-di-N-oxide-quinoxaline derivatives and 11 concerning quinoxaline derivatives) were published, respectively.

4. Discussion

4.1. Quinoxaline Derivatives as Antimycobacterial Agents

A wide variety of methods for the synthesis of functionalized quinoxalines have already been reported in the literature. In general, quinoxaline derivatives are obtained either by condensation of o-phenylenediamine and its derivatives with a dicarbonyl compound under conventional conditions or reaction of 1,2-diaza-1,3-butadienes with 1,2-diamines [19,20,21,22]. Eco-friendly approaches using recyclable catalysts [23,24], oxidative cyclisation of 1,2-diamines and phenacyl bromides [25], microwave-assisted synthesis [26,27], reactions in aqueous medium [28], or one-pot synthesis [29] have also been described.

4.1.1. Tricyclic Quinoxaline Derivatives

Between 2017 and 2020, three series of original benzo[g]quinoxaline-5,10-dione derivatives were synthesized using a multistep synthetic route from 2,3-dihydroxynaphtalene and evaluated as potential antimycobacterial agents [30,31,32] (Figure 2).
Thirteen novel compounds belonging to the pyridine series, 11 new pyrazoline derivatives, and 11 7-[3-(substituted) phenylprop-2-enoyl]quinoxaline derivatives were obtained; they displayed moderate antimycobacterial activity [30,31,32] (Table 3).
Pyrroloquinoxaline moiety represents a very attractive scaffold in medicinal chemistry for its biological anti-infectious properties, including antimycobacterial activity [33]. This, pyrrolo[1,2-a]quinoxaline was chosen as scaffold and led to the synthesis of 23 new pyrrolo[1,2-a]quinoxaline derivatives (Figure 3) that displayed very encouraging antimycobacterial activity [34].
Ten compounds showed both interesting antimycobacterial activity and moderate cytotoxicity. Antimycobacterial activity was observed to depend on varying chemical characteristics, like the replacement of tertiary nitrogen by an NH group, leading to compounds 7–10 with improved solubility and the lowest minimal inhibitory concentration (MIC) value (5 µg/mL) (Table 4).
Modification of the linker between R2 and pyrrolo[1,2-a]quinoxaline moiety led to a minor variation in antibacterial activity, although substitutions at the R2 position with an aromatic group led to the most active compounds (Figure 4). Derivative N-((7-chloro-1-(2-fluorophenyl)pyrrolo[1,2-a]quinoxalin-3-yl)methyl)-2-(3,4-dimethoxyphenyl)ethanamine (9) was identified as offering the best oral bioavailability. Determination of enzyme inhibition and molecular docking studies revealed that these original derivatives could act by targeting the classic anti-TB drug target InhA by forming H bonds as well as Pi–Pi interactions.
In addition, several novel 4,5-dihydropyrrolo[1,2-a]quinoxalines and pyrrolo[1,2-a]quinoxaline-2-ones were synthesized from the reaction between 2-(1H-pyrrol-1-yl)anilines and imidazo[1,2-a]pyridine-3-carbaldehyde or isatin and are of current interest as antimycobacterial agents [35] (Figure 5).
Five 4-substitued 4,5-dihydropyrrolo[1,2-a]quinoxalines and only one pyrrolo[1,2-a]quinoxaline-2-one derivative displayed potent antimycobacterial activity, with MIC ranging from 6.25 to 12.5 µg/mL. However, no clear structure–activity relationship could be demonstrated from the small number of synthesized compounds [35].

4.1.2. Hybrids and Conjugates

Many classes of organic compounds have previously been evaluated for their anti-mycobacterial activity. A rational design strategy based on combining the biological properties of different bioactive structures into a single compound could lead to new compounds with increased activity, combined modes of action, or improved tolerance profiles compared to parent structures.
Then, the quinoxaline ring fused with azetidinone and thiazolidinone, two structural scaffolds possessing antitubercular activity [36,37,38], showed in vitro activity against Mycobacterium tuberculosis. Quinoxaline derivatives with 2-chloro, dimethylamino and nitro substitution showed comparable activity to that of isoniazid (MIC = 0.67–0.97 µg/mL versus 0.46 µg/mL) [39] (Figure 6).
As vitamin B6 is an important cofactor in a large number of important enzymic reactions and is also used in bioinorganic chemistry as a ligand, a new series of 13 quinoxalines bearing the pyridoxal moiety was synthesized and tested against Mycobacterium tuberculosis (Figure 7). In a hydrazone series, the 7-chloroquinoxaline derivative (11) showed the best activity, with the MIC of 72.72 µM. The number of nitrogen and chlorine atoms in the radical moiety plays an important role in antimycobacterial activity [40].
In order to prevent excessive toxicity due to high lipophilicity and considering the biosafety profile of sugar conjugates [41,42,43], some new sugar conjugates of quinoxaline were synthesized and evaluated for their antitubercular activity. Of a series of six sugar conjugates of quinoxaline compounds, all the synthesized derivatives demonstrated interesting antimycobacterial activity, with the MIC ranging from 0.65 to 9.6 µM [43] (Figure 8).
The ribose conjugate (13e) exhibited the best antimycobacterial activity, with the MIC = 0.65 µM. All the sugar conjugates were more active than the initial quinoxaline-2,3-(1H,4H)-dione and the intermediate 3-hydrazono-3,4-dihydroquinoxalin-2(1H)-one at the MIC > 59.2 µM and the MIC = 27.2 µM, respectively. The structure–activity relationship showed that monosaccharides had better activity than disaccharides and that the aldopentoses were more potent than the aldohexoses. As in silico docking analysis revealed that these compounds could interact with DNA gyrase, it was concluded that the stereoisomerism of sugar may influence antimycobacterial activity; this was supported by the fact that the ribose derivative was seven times more potent than the xylose derivative.
Chalcones are compounds with a wide range of biological activities, including antitubercular activity [44,45]. Of a series of 14 original quinoxalinyl chalcones, two derivatives demonstrated equivalent activity to pyrazinamide and ciprofloxacin taken as reference with the MIC = 3.12 µg/mL. The structure–activity relationship showed that the presence of a hydroxyl substituent at position 3 on the phenyl ring increases antimycobacterial activity. Replacing phenyl with naphthyl resulted in reduced antimycobacterial activity, indicating that the hydrophobicity/lipophilicity balance plays an important role in these derivatives’ activity [46] (Table 5).
The efficacy of quinoxaline-derived chalcones has recently been confirmed by the preclinical evaluation of a new series of derivatives. Of the synthesized compounds, six molecules inhibited Mycobacterium tuberculosis growth, with the MIC ranging from 3.13 to 12.5 µg/mL [47]. Further investigations on the lead compound (20) also demonstrated that this derivative exhibited synergistic effect with moxifloxacin and did not cause mutagenicity or genotoxicity (Table 6).
In addition, the modification of nalidixic acid, a representative of the quinolone and fluoroquinolone antibiotics which are an essential component of treatment strategies for drug-resistant TB [1], on its –COOH group led to the formation of original quinoxaline conjugates which showed encouraging antimycobacterial activity. Among the synthesized derivatives, quinoxalines with azide as side chain (25 and 26) exhibited the two best activities, with the percentage of inhibition of Mycobacterium tuberculosis at 6.25 µg/mL of 93% and 91%, respectively, compared to 100% for ciprofloxacin taken as reference [48] (Figure 9).
As Schiff bases possess antimicrobial and antitubercular properties [49], synthesis of some quinoxaline-incorporated Schiff bases was performed. Among an original series of ten different Schiff bases resulting from the reaction between 2-((3-methylquinoxalin-2-yl)oxy)acetohydrazide (31) and various heterocyclic/aromatic aldehydes, five compounds exhibited potent antitubercular activity [49] (Figure 10).
Finally, spiroheterocyclic structures are well known for their antimycobacterial properties [50,51]. Spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids were synthesized and evaluated against Mycobacterium tuberculosis. Of the 11 synthesized compounds, bearing m-nitro, p-bromo and o-chloro substituents on the aryl ring showed interesting antimycobacterial activity, with MIC values ranging from 1.56 to 6.25 µg/mL [52] (Table 7).

4.1.3. Other Structures

Several derivatives of 2-substituted quinoxalines have also shown interesting antitubercular activities. Thus, quinoxaline alkynyl derivatives demonstrated antimycobacterial activity. Of the 19 original quinoxalines bearing diverse substituents on the alkynyl group synthesized from quinoxaline-2-ol derivatives, seven compounds had MIC90 < 10 µM and five compounds had MIC90 ranging from 10 to 20 µM [53] (Table 8).
The presence of an electron-withdrawing group at the C6 position of the quinoxaline moiety plays an important role in antimycobacterial activity: four of the most active compounds are derivatives bearing NO2 at this position with MIC90 < 3 µM.
Moreover, screening of a library of compounds identified three original 2-carboxyquinoxaline compounds showing activity against Mycobacterium tuberculosis with MIC99 values ranging from 3.1 to 12.5 µM [54]. Among them, the lead compound (39) which exhibited a MIC99 of 3.1 µM was shown to noncovalently and noncompetitively inhibit DprE1, an enzyme essential for bacterial wall synthesis by forming hydrophobic interactions and hydrogen bonds (Figure 11).

4.2. Quinoxaline-1,4-di-N-oxide Derivatives Active against Mycobacterium tuberculosis

Quinoxaline-1,4-di-N-oxide derivatives are a class of compounds with a variety of biological properties, including antitumor, anti-inflammatory, and anti-infectious activity [2]. The classic method of quinoxaline-1,4-di-N-oxide preparation uses benzofuroxane N-oxide as the reagent [55].

4.2.1. Hybrids and Conjugates

1,2,3-triazole and their derivatives are known for their various biological activities including antifungal and antibacterial activity [56]. In order to study the influence of the substitution at the C2 position in quinoxaline-1,4-di-N-oxide series, thirty-one 1,2,3-triazole analogs of quinoxaline-1,4-di-N-oxide were synthesized and evaluated against Mycobacterium tuberculosis, yielding 16 compounds with the MIC ranging from 12.5 to 25 µg/mL [56] (Figure 12).
More specifically, in 2-(((1-(substituted phenyl)-1H-1,2,3-triazol-4-yl)methoxy)carbonyl)-3-methylquinoxaline-1,4-dioxide series, only 2-chloro and 2- or 3-nitro compounds exhibited high activity. In 3-(((1-(substituted phenyl)-1H-1,2,3-triazol-4-yl)methoxy)carbonyl)-6-chloro-2-methylquinoxaline-1,4-dioxide series, unsubstituted, ortho-, and para-substituted derivatives exhibited high activity. The most active compound of the three series, 6-chloro-2-methyl-3-(((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)carbonyl)quinoxaline-1,4-dioxide, exhibited good antimycobacterial activity, with the MIC of 12.5 μg/mL against the tested strains versus 3.1 µg/mL for reference drug isoniazid. In the 2-(((1-(substituted phenyl)-1H-1,2,3-triazol-4-yl)methoxy)carbonyl)-6,7-dichloro-3-methylquinoxaline-1,4-dioxide series, only para-substituted halogen compounds exhibited activity. These structure–activity relationships also demonstrated that the introduction of an electron-withdrawing group resulted in less active compounds.
In addition, hybridization of quinoxaline 1,4-di-N-oxide with chalcone, fluoroquinolone, and thiazolidinone scaffolds was investigated [57,58]. Of the 10 original chalcones newly synthesized by Claisen–Schmidt condensation, only one displayed potency, with the MIC = 3.1 µM compared to 6.2 µM, 0.3 µM, and 0.04 µM, respectively, for ethambutol, isoniazid, and rifampicin taken as reference. In this same study, four of the five most potent derivatives were fluoroquinolone analogs, with MIC values ranging from 1.6 to 3.1 µM (Table 9). The structure–activity relationship showed that the presence of an electron-withdrawing substituent like a halogen atom at position C6 or C7 of the quinoxaline moiety enhances the activity. In addition, the presence of CF3 at position C3 promotes antimycobacterial activity, while the nature of the lateral side chain substituent at the C2 position of the quinoxaline group seems to have less influence on biological activity [57].
In thiazolidinone series, out of 26 novel derivatives, four compounds displayed potent antimycobacterial activity, four compounds—moderate activity [58] (Table 10). The presence of an electron-withdrawing group at the para position of the phenyl group is essential for higher activity and the presence of a halogen atom at position C7 of the quinoxaline nucleus increases antimycobacterial activity. Replacement of halogen atoms with a methyl or methoxy resulted in decreased antimycobacterial activity.
As many isonicotinic acid hydrazide derivatives such as isoniazid demonstrated interesting anti-TB activities, an original series of hybrids resulting from the fusion between quinoxaline 1,4-di-N-oxide and isoniazid was synthetized; it showed high activity against Mycobacterium tuberculosis, with IC90 ranging from <1.16 to 50.60 µM versus 0.21 µM for isoniazid taken as reference (Figure 13). As isonicotinic hydrazide derivatives can be considered as a prodrug, these new hybrids could act according to the original mechanism of action where the hydrolysis of the compounds would lead to the formation of isoniazid which would act according to its own mechanism of action and of quinoxaline derivatives which would act synergistically with isoniazid. Position 7 unsubstituted or substituted by an electron-withdrawing or electron-releasing group does not differ in activity [59].
The quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives used as precursors for the synthesis of these new series were also evaluated against Mycobacterium tuberculosis. In these series, molecules substituted with an electron-withdrawing group at position 7 such as CF3, Cl, or F on the quinoxaline ring were the most active compounds, with the respective IC90 of 1.07, 1.25, and 4.65 µM. In order to explore the structural requirements for anti-TB activity, molecular modelling studies were performed on a series of 23 original quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives, with IC90 values ranging from 3.86 µg to 100 µg [60]. The reliable pharmacophore generated was composed of one aromatic ring, four hydrophobic substituents, three hydrogen acceptors, and one hydrogen donor. The binding mode of these derivatives was similar to that of coumarin in novobiocin, which is known to be an inhibitor of Mycobacterium tuberculosis DNA gyrase active site.

4.2.2. Other Structures

In order to develop new antitubercular agents, a series of 33 original quinoxaline-1,4-di-N-oxide derivatives variously substituted at the C2 position were synthesized and evaluated [61]. Of these, 17 showed significant activity against Mycobacterium tuberculosis, with the MIC ranging from 0.39 to 6.25 µg/mL and no cytotoxic effects on VERO cells (Table 11). Compounds bearing a thioether linkage and a sterically bulky aromatic group at the terminal side chain on the C2 position are the best representatives of these original series.
Additionally, the inhibitory effect of methyl, ethyl, isopropyl, and n-propyl esters of quinoxaline 1,4-di-N-oxide on Mycobacterium tuberculosis was assessed [62]. Of the 18 original esters of the 1,4-di-N-oxide synthesized, eight derivatives showed similar activity to that of isoniazid taken as reference (Table 12).
The steric effect of the ester group at position 7 plays a crucial role in enhancing biological effects. The (CH3)2CH substituent at position 7 enhances antimycobacterial activity. COOCH3 or COOCH2CH3 attached at position 2 on the quinoxaline ring and CF3 substituent at position 3 also result in increased antimycobacterial activity.
Influence of substitution at positions 2, 3, and 7 was also assessed in a new series of 22 new N-oxide-containing compounds leading to the synthesis of nine quinoxaline 1,4-di-N-oxide derivatives [63] (Figure 14).
For quinoxaline phenyl derivatives, MIC90 values ranged from 12 to 30.8 µM versus 0.1 µM for the standard drugs isoniazid and rifampicin taken as reference. Antimycobacterial activity was affected by the presence of a para substituent on the phenyl ring: absence of substitution led to the derivative with lowest activity while the derivatives substituted by a methoxy group displayed the highest activity. However, no clear evidence of impact from electron-withdrawing and electron-donating groups was observed. In addition, isosteric substitution of the phenyl ring by furan led to a more active compound, with MIC90 of 5.2 µM.

5. Conclusions

This review highlights the growing interest in the development of compounds bearing a quinoxaline moiety for antimycobacterial treatment, some of these compounds having reached the preclinical evaluation phase. From the published studies, both quinoxaline and quinoxaline-1,4-di-N-oxides with a variety of substituents in positions 2, 3, 6, and 7 showed anti-TB activity. From these data, it appears that the quinoxaline moiety represents an interesting scaffold against Mycobacterium tuberculosis. Some structure–activity relationships can be proposed for further investigations on this scaffold. Firstly, it appears that quinoxaline derivatives with the most potent antimycobacterial activity are unsubstituted at positions 1, 4, 5, and 8, although the presence of the pyrrolo substituent at position 1 does not result in a loss of biological activity. Substituents in positions 2 and 3 appear to play an important role in anti-TB activity as the presence of alkynyl derivatives, azide, hydrazone or acylhydrazone, chalcone, azetidinone, thiazolidinone, carboxylic acid substituent leads to significant activity. Various substituents such as thioether linkage, ester, carboxamide, chalcone, ketone, thiazolidinone, or hydrazide at position 2 lead to derivatives with potent antimycobacterial activity in quinoxaline 1,4-di-N-oxide series. The presence of a trifluoromethyl or methoxy group at position 3 of the quinoxaline moiety increases the activity. Substitution at positions 6 and 7 is not crucial, but derivatives substituted with ester, halogen, nitro, trifluoromethyl group, chalcone, or heterocycle at these positions exhibited excellent antimycobacterial activity. Hybridization of different pharmacophoric moieties with a quinoxaline nucleus might help to develop an effective molecule for TB treatment. These results warrant further investigations, which may allow identification of novel antitubercular candidates based on this scaffold.

Author Contributions

Conceptualization and methodology, M.M.; formal analysis, M.M. and V.M.; data curation, V.M. and M.M.; writing—original draft preparation, M.M. and V.M.; writing—review and editing, O.K. and P.V.; supervision, P.V. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. WHO. Global Tuberculosis Report 2020. Available online: https://www.who.int/publications/i/item/9789240013131 (accessed on 16 April 2021).
  2. Keri, R.S.; Pandule, S.S.; Budagumpi, S.; Nagaraja, B.M. Quinoxaline and quinoxaline-1,4-di-N-oxides: An emerging class of antimycobacterials. Arch. Pharm. (Weinh.) 2018, 351, e1700325. [Google Scholar] [CrossRef]
  3. Barthod, L.; Lopez, J.G.; Curti, C.; Bornet, C.; Roche, M.; Montana, M.; Vanelle, P. News on therapeutic management of MDR-tuberculosis: A literature review. J. Chemother. 2018, 30, 1–15. [Google Scholar] [CrossRef]
  4. Shagufta; Ahmad, I. An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. MedChemCom 2017, 8, 871–885. [Google Scholar] [CrossRef]
  5. Kalaria, P.N.; Karad, S.C.; Raval, D.K. A review on diverse heterocyclic compounds as the privileged scaffolds in antimalarial drug discovery. Eur. J. Med. Chem. 2018, 158, 917–936. [Google Scholar] [CrossRef]
  6. Kerru, N.; Gummidi, L.; Maddila, S.; Gangu, K.K.; Jonnalagadda, S.B. A Review on Recent Advances in Nitrogen-Containing Molecules and Their Biological Applications. Molecules 2020, 25, 1909. [Google Scholar] [CrossRef] [PubMed]
  7. Heravi, M.M.; Zadsirjan, V. Prescribed drugs containing nitrogen heterocycles: An overview. RCS Adv. 2020, 10, 44247–44311. [Google Scholar]
  8. Deepika, Y.; Nath, P.S.; Sachin, K.; Shewta, S. Biological activity of quinoxaline derivatives. Int. J. Curr. Pharm. Res. 2011, 2, 33–46. [Google Scholar]
  9. Montana, M.; Montero, V.; Khoumeri, O.; Vanelle, P. Quinoxaline Derivatives as Antiviral Agents: A Systematic Review. Molecules 2020, 25, 2784. [Google Scholar] [CrossRef] [PubMed]
  10. Montana, M.; Mathias, F.; Terme, T.; Vanelle, P. Antitumoral activity of quinoxaline derivatives: A systematic review. Eur. J. Med. Chem. 2019, 163, 136–147. [Google Scholar] [CrossRef]
  11. Barea, C.; Pabón, A.; Pérez-Silanes, S.; Galiano, S.; Gonzalez, G.; Monge, A.; Deharo, E.; Aldana, I. New Amide Derivatives of Quinoxaline 1,4-di-N-Oxide with Leishmanicidal and Antiplasmodial Activities. Molecules 2013, 18, 4718–4727. [Google Scholar] [CrossRef]
  12. González, M.; Cerecetto, H. Quinoxaline derivatives: A patent review (2006–present). Expert Opin. Ther. Pat. 2012, 22, 1289–1302. [Google Scholar] [CrossRef] [PubMed]
  13. Zanetti, S.; Sechi, L.A.; Molicotti, P.; Cannas, S.; Bua, A.; Deriu, A.; Carta, A.; Paglietti, G. In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria. Int. J. Antimicrob. Agents 2005, 25, 179–181. [Google Scholar] [CrossRef]
  14. Ortega, M.A.; Montoya, M.E.; Jaso, A.; Zarranz, B.; Tirapu, I.; Aldana, I.; Monge, A. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Pharmazie 2001, 56, 205–207. [Google Scholar] [CrossRef]
  15. Villar, R.; Vicente, E.; Solano, B.; Perez-Silanes, S.; Aldana, I.; Maddry, J.A.; Lenaerts, A.J.; Franzblau, S.G.; Cho, S.H.; Monge, A.; et al. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J. Antimicrob. Chemother. 2008, 62, 547–554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Crawford, P.W.; Scamehorn, R.G.; Hollstein, U.; Ryan, M.D.; Kovacic, P. Cyclic voltammetry of phenazines and quinoxalines including mono- and di-N-oxides. Relation to structure and antimicrobial activity. Chem. Biol. Interact. 1986, 60, 67. [Google Scholar] [CrossRef]
  17. Chowdhury, G.; Kotandeniya, D.; Daniels, J.S.; Barnes, C.L.; Gates, K.S. Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide. Chem. Res. Toxicol. 2004, 17, 1399–1405. [Google Scholar] [CrossRef] [PubMed]
  18. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009, 3, 123–130. [Google Scholar]
  19. Cheeseman, G.W.H.; Cookson, R.F. Condensed Pyrazines. In The Chemistry of Heterocyclic Compounds; Weissberger, A., Taylor, E.C., Eds.; John Wiley & Sons, Inc.: New York, NY, USA, 1979; Volume 35, pp. 78–111. [Google Scholar]
  20. Pereira, J.A.; Pessoa, A.M.; Cordeiro, M.N.D.S.; Fernandes, R.; Prudencio, C.; Noronha, J.P.; Vieira, M. Quinoxaline, its derivative and applications: A state of the art review. Eur. J. Med. Chem. 2015, 97, 664–672. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Brown, D.J.; Ellman, J.A. The Chemistry of Heterocyclic Compounds; Wiley: New York, NY, USA, 2004. [Google Scholar]
  22. Aparicio, D.; Attanasi, O.A.; Filippone, P.; Ignacio, R.; Lillini, S.; Mantellini, F.; Palacios, F.; De Los Santos, J.M. Straightforward access to pyrazines, piperazinones, and quinoxalines by reactions of 1,2-diaza-1,3-butadienes with 1,2-diamines under solution, solvent-free, or solid-phase conditions. J. Org. Chem. 2006, 71, 5897–5905. [Google Scholar] [CrossRef] [PubMed]
  23. Cai, J.J.; Zou, J.P.; Pan, X.Q.; Zhang, W. Gallium triflate catalyzed synthesis of quinoxaline derivatives. Tetrahedron Lett. 2008, 49, 7386–7390. [Google Scholar] [CrossRef]
  24. Antoniotti, S.; Dunach, E. Direct and catalytic synthesis of quinoxaline derivatives from epoxides and ene-1,2-diamines. Tetrahedron Lett. 2002, 43, 3971–3973. [Google Scholar] [CrossRef]
  25. Kumar, K.; Mudshinge, S.R.; Goyal, S.; Gangar, M.; Nair, V.A. A catalyst free, one pot approach for the synthesis of quinoxaline derivatives via oxidative cyclisation of 1,2-diamines and phenacyl bromides. Tetrahedron Lett. 2015, 56, 1266–1271. [Google Scholar] [CrossRef]
  26. Gris, J.; Glisoni, R.; Fabian, L.; Fernandez, B.; Moglioni, A.G. Synthesis of potential chemotherapic quinoxalinone derivatives by biocatalysis or microwave-assisted Hinserg reaction. Tetrahedron Lett. 2008, 49, 1053–1056. [Google Scholar] [CrossRef]
  27. Rostamizadeh, S.; Jafari, S. The synthesis of quinoxalines under microwave irradiation. Indian J. Heterocycl. Chem. 2001, 10, 303–304. [Google Scholar]
  28. Shaabani, A.; Maleki, A. Green and efficient synthesis of quinoxaline derivatives via ceric ammonium nitrate promoted and in situ aerobic oxidation of alpha-hydroxy ketones and alpha-keto oximes in aqueous media. Chem. Pharm. Bull. 2008, 56, 79–81. [Google Scholar] [CrossRef] [Green Version]
  29. Thakuria, H.; Das, G. One-pot efficient green synthesis of 1,4-dihydroquinoxaline-2,3-dione derivatives. J. Chem. Sci. 2006, 118, 425–428. [Google Scholar] [CrossRef]
  30. Kumar, S.; Kumar, N.; Drabu, S. Synthesis of benzo[g]quinoxaline-5,10-dione based pyridine derivatives and their antimycobacterial activity. Orient. J. Chem. 2017, 33, 821–828. [Google Scholar] [CrossRef]
  31. Kumar, S.; Kumar, N.; Drabu, S. Synthesis of benzo[g]quinoxaline-5,10-dione based pyrazoline derivatives and their antimycobacterial activity. Int. J. Pharm. Sci. Res. 2018, 9, 498–508. [Google Scholar]
  32. Kumar, S.; Kumar, N.; Drabu, S. Synthesis and in vitro antimycobacterial activity of 7-[3-(substituted) phenylprop-2-enoyl]-2,3-diphenyl-5H,10H-benzo[g]quinoxaline-5,10-diones. Indian J. Heterocycl. Chem. 2017, 27, 25–31. [Google Scholar]
  33. Guillon, J.; Reynolds, R.C.; Leger, J.M.; Guie, M.A.; Massip, S.; Dallemagne, P.; Jarry, C. Synthesis and preliminary in vitro evaluation of antimycobacterial activity of new pyrrolo[1,2-a]quinoxaline-carboxylic acid hydrazide derivatives. J. Enzym. Inhib. Med. Chem. 2004, 19, 489–495. [Google Scholar] [CrossRef] [Green Version]
  34. Wang, T.; Tang, Y.; Yang, Y.; An, Q.; Sang, Z.; Yang, T.; Liu, P.; Zhang, T.; Deng, Y.; Luo, Y. Discovery of novel tuberculosis agents with pyrrolo[1,2-a]quinoxaline based scaffold. Bioorg. Med. Chem. Lett. 2018, 28, 2084–2090. [Google Scholar] [CrossRef]
  35. Makane, V.B.; Vamshi Krishna, E.; Karale, U.B.; Babar, D.A.; Kalari, S.; Rekha, E.M.; Shukla, M.; Kaul, G.; Sriram, D.; Chopra, S.; et al. Synthesis of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines, pyrrolo[1,2-a]quinoxalin]-2-ones and their antituberculosis and anticancer activity. Arch. Pharm. (Weinh.) 2020, 353, e2000192. [Google Scholar] [CrossRef] [PubMed]
  36. Vijaykumar, M.M.; Nagaraja, T.S.; Shameer, H.; Jayachandran, E.; Sreenivasa, G.M. N-substituted-3-chloro-2-azetidinones: Synthesis and characterization of new novel anti-inflammatory agents. J. Pharm. Sci. Res. 2009, 1, 83–92. [Google Scholar]
  37. Sandip, J.; Mahesh, P.; Veeresh, M.; Pradeepkumar, R.; Shivalingarao, M.; Satyanarayana, D.; Mangala, G. Synthesis and antimycobacterial activity of a novel series of isonicotinyl hydrazide derivatives. Arch. Pharm. Chem. Life Sci. 2009, 342, 723–731. [Google Scholar]
  38. Amit, V.; Shailendra, K.S. 4-Thiazolidinone—A biologically active scaffold. Eur. J. Med. Chem. 2008, 43, 897–905. [Google Scholar]
  39. Puratchikody, A.; Natarajan, R.; Jayapal, M.; Doble, M. Synthesis, in vitro antitubercular activity and 3D-QSAR of novel quinoxaline derivatives. Chem. Biol. Drug Des. 2011, 78, 988–998. [Google Scholar] [CrossRef] [PubMed]
  40. Nogueira, T.C.M.; dos Santos Cruz, L.; Lourenço, M.C.; de Souza, M.V.N. Design, synthesis and anti-tuberculosis activity of hydrazones and n-acylhydrazones containing vitamin B6 and different heteroaromatic nucleus. Lett. Drug Des. Discov. 2019, 16, 792–798. [Google Scholar] [CrossRef]
  41. Calvaresi, E.C.; Hergenrother, P.J. Glucose conjugation for the specific targeting and treatment of cancer. Chem. Sci. 2013, 4, 2319–2333. [Google Scholar] [CrossRef] [Green Version]
  42. Xavier, N.M.; Goulart, M.; Neves, A.; Justino, J.; Chambert, S.; Rauter, A.P.; Queneau, Y. Synthesis of sugars embodying conjugated carbonyl systems and related triazole derivatives from carboxymethyl glycoside lactones. Evaluation of their antimicrobial activity and toxicity. Bioorg. Chem. 2011, 19, 926–938. [Google Scholar] [CrossRef] [Green Version]
  43. Peraman, R.; Kuppusamy, R.; Killi, S.K.; Reddy, Y.P. New Conjugates of Quinoxaline as Potent Antitubercular and Antibacterial Agents. Int. J. Med. Chem. 2016, 2016, 6471352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Gomes, M.N.; Braga, R.C.; Grzelak, E.M.; Neves, B.J.; Muratov, E.N.; Ma, R.; Klein, L.L.; Cho, S.; Oliveira, G.R.; Franzblau, S.G.; et al. QSAR-driven design, synthesis and discovery of potent and selective chalcone derivatives with antitubercular activity. Eur. J. Med. Chem. 2017, 137, 126–138. [Google Scholar] [CrossRef] [PubMed]
  45. Lin, Y.M.; Zhou, Y.; Flavin, M.; Zhou, L.M.; Nie, W.; Chen, F.C. Chalcones and flavonoids as anti-tuberculosis agents. Bioorg. Med. Chem. 2002, 10, 2795–2802. [Google Scholar] [CrossRef]
  46. Desai, V.G.; Desai, S.R.; Gaonkar, S.N.; Palyekar, U.; Joshi, S.; Dixit, S. Novel quinoxalinyl chalcone hybrid scaffolds as enoyl ACP reductase inhibitors: Synthesis, molecular docking and biological evaluation. Bioorg. Med. Chem. Lett. 2017, 27, 2174–2180. [Google Scholar] [CrossRef] [PubMed]
  47. Muradás, T.C.; Abbadi, B.L.; Villela, A.D.; Macchi, F.S.; Bergo, P.F.; de Freitas, T.F.; Sperotto, N.; Timmers, L.; Norberto de Souza, O.; Picada, J.N.; et al. Pre-clinical evaluation of quinoxaline-derived chalcones in tuberculosis. PLoS ONE 2018, 13, e0202568. [Google Scholar]
  48. Peraman, R.; Varma, R.V.; Reddy, Y.P. Re-engineering nalidixic acid’s chemical scaffold: A step towards the development of novel anti-tubercular and anti-bacterial leads for resistant pathogens. Bioorg. Med. Chem. Lett. 2015, 25, 4314–4319. [Google Scholar] [CrossRef] [PubMed]
  49. Achutha, L.; Parameshwar, R.; Madhava Reddy, B.; Harinadha Babu, V. Microwave-Assisted Synthesis of Some Quinoxaline-Incorporated Schiff Bases and Their Biological Evaluation. J. Chem. 2013, 2013, 578438. [Google Scholar] [CrossRef]
  50. Kumar, R.R.; Perumal, S.; Senthilkumar, P.; Yogeeswari, P.; Sriram, D. Discovery of antimycobacterial spiro-piperidin-4-ones: An atom economic, stereoselective synthesis, and biological intervention. J. Med. Chem. 2008, 51, 5731–5735. [Google Scholar] [CrossRef]
  51. Prasanna, P.; Balamurugan, K.; Perumal, S.; Yogeeswari, P.; Sriram, D. A regio- and stereoselective 1,3-dipolar cycloaddition for the synthesis of novel spiro-pyrrolothiazolyloxindoles and their antitubercular evaluation. Eur. J. Med. Chem. 2010, 45, 5653–5661. [Google Scholar] [CrossRef]
  52. Arumugam, N.; Almansour, A.I.; Suresh Kumar, R.; Ibrahim Alaqeel, S.; Siva Krishna, V.; Sriram, D. Anti-tubercular activity of novel class of spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids. Bioorg. Chem. 2020, 99, 103799. [Google Scholar] [CrossRef]
  53. Raphoko, L.A.; Lekgau, K.; Lebepe, C.M.; Leboho, T.C.; Matsebatlela, T.M.; Nxumalo, W. Synthesis of novel quinoxaline-alkynyl derivatives and their anti-Mycobacterium tuberculosis activity. Bioorg. Med. Chem. Lett. 2021, 35, 127784. [Google Scholar] [CrossRef]
  54. Neres, J.; Hartkoorn, R.C.; Chiarelli, L.R.; Gadupudi, R.; Pasca, M.R.; Mori, G.; Venturelli, A.; Savina, S.; Makarov, V.; Kolly, G.S.; et al. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. ACS Chem. Biol. 2015, 10, 705–714. [Google Scholar] [CrossRef]
  55. Xu, Y.; Wu, F.; Yao, Z.; Zhang, M.; Jiang, S. Synthesis of quinoxaline 1,4-di-N-oxide analogues and crystal structure of 2-carbomethoxy-3-hydroxyquinoxaline-di-N-oxide. Molecules 2011, 16, 6894–6901. [Google Scholar] [CrossRef] [Green Version]
  56. Srinivasarao, S.; Nandikolla, A.; Suresh, A.; Ewa, A.K.; Głogowska, A.; Ghosh, B.; Kumar, B.K.; Murugesan, S.; Pulya, S.; Aggarwal, H.; et al. Discovery of 1,2,3-triazole based quinoxaline-1,4-di-N-oxide derivatives as potential anti-tubercular agents. Bioorg. Med. Chem. 2020, 100, 103955. [Google Scholar] [CrossRef]
  57. Santivañez-Veliz, M.; Pérez-Silanes, S.; Torres, E.; Moreno-Viguri, E. Design and synthesis of novel quinoxaline derivatives as potential candidates for treatment of multidrug-resistant and latent tuberculosis. Bioorg. Med. Chem. Lett. 2016, 26, 2188–2193. [Google Scholar] [CrossRef] [Green Version]
  58. Zhang, H.; Zhang, J.; Qu, W.; Xie, S.; Huang, L.; Chen, D.; Tao, Y.; Liu, Z.; Pan, Y.; Yuan, Z. Design, Synthesis, and Biological Evaluation of Novel Thiazolidinone-Containing Quinoxaline-1,4-di-N-oxides as Antimycobacterial and Antifungal Agents. Front. Chem. 2020, 8, 598. [Google Scholar] [CrossRef]
  59. Torres, E.; Moreno, E.; Ancizu, S.; Barea, C.; Galiano, S.; Aldana, I.; Monge, A.; Pérez-Silanes, S. New 1,4-di-N-oxide-quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives as anti-Mycobacterium tuberculosis agents. Bioorg. Med. Chem. Lett. 2011, 21, 3699–3703. [Google Scholar] [CrossRef]
  60. Radwan, A.A.; Abdel-Mageed, W.M. In Silico Studies of Quinoxaline-2-Carboxamide 1,4-di-N-Oxide Derivatives as Antimycobacterial Agents. Molecules 2014, 19, 2247–2260. [Google Scholar] [CrossRef] [Green Version]
  61. Pan, Y.; Li, P.; Xie, S.; Tao, Y.; Chen, D.; Dai, M.; Hao, H.; Huang, L.; Wang, Y.; Wang, L.; et al. Synthesis, 3D-QSAR analysis and biological evaluation of quinoxaline 1,4-di-N-oxide derivatives as antituberculosis agents. Bioorg. Med. Chem. Lett. 2016, 26, 4146–4153. [Google Scholar] [CrossRef]
  62. Palos, I.; Luna-Herrera, J.; Lara-Ramírez, E.E.; Loera-Piedra, A.; Fernández-Ramírez, E.; Aguilera-Arreola, M.G.; Paz-González, A.D.; Monge, A.; Wan, B.; Franzblau, S.; et al. Anti-Mycobacterium tuberculosis Activity of Esters of Quinoxaline 1,4-Di-N-Oxide. Molecules 2018, 23, 1453. [Google Scholar] [CrossRef] [Green Version]
  63. Dos Santos Fernandes, G.F.; de Souza, P.C.; Moreno-Viguri, E.; Santivañez-Veliz, M.; Paucar, R.; Pérez-Silanes, S.; Chegaev, K.; Guglielmo, S.; Lazzarato, L.; Fruttero, R.; et al. Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. J. Med. Chem. 2017, 60, 8647–8660. [Google Scholar] [CrossRef] [Green Version]
Molecules 26 04742 g001 550
Figure 1. Chemical structure of clofazimine.
Figure 1. Chemical structure of clofazimine.
Molecules 26 04742 g001
Molecules 26 04742 g002 550
Figure 2. Chemical structures of new series benzo[g]quinoxaline-5,10-dione derivatives.
Figure 2. Chemical structures of new series benzo[g]quinoxaline-5,10-dione derivatives.
Molecules 26 04742 g002
Molecules 26 04742 g003 550
Figure 3. Chemical structures of new series of pyrrolo[1,2-a]quinoxaline derivatives.
Figure 3. Chemical structures of new series of pyrrolo[1,2-a]quinoxaline derivatives.
Molecules 26 04742 g003
Molecules 26 04742 g004 550
Figure 4. Structure–activity relationship of novel quinoxaline derivatives with antimycobacterial activity.
Figure 4. Structure–activity relationship of novel quinoxaline derivatives with antimycobacterial activity.
Molecules 26 04742 g004
Molecules 26 04742 g005 550
Figure 5. General structure of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines and pyrrolo[1,2-a]quinoxaline-2-ones synthesized.
Figure 5. General structure of novel 4,5-dihydropyrrolo[1,2-a]quinoxalines and pyrrolo[1,2-a]quinoxaline-2-ones synthesized.
Molecules 26 04742 g005
Molecules 26 04742 g006 550
Figure 6. General structure of original quinoxaline derivatives containing azetidinone and thiazolidinone moieties.
Figure 6. General structure of original quinoxaline derivatives containing azetidinone and thiazolidinone moieties.
Molecules 26 04742 g006
Molecules 26 04742 g007 550
Figure 7. Lead compound of hydrazones and N-acylhydrazones containing vitamin B6 and different heteroaromatic nuclei.
Figure 7. Lead compound of hydrazones and N-acylhydrazones containing vitamin B6 and different heteroaromatic nuclei.
Molecules 26 04742 g007
Molecules 26 04742 g008 550
Figure 8. Schematic route for the synthesis of sugar conjugates of quinoxaline.
Figure 8. Schematic route for the synthesis of sugar conjugates of quinoxaline.
Molecules 26 04742 g008
Molecules 26 04742 g009 550
Figure 9. Chemical structures of lead compounds in nalidixic acid series.
Figure 9. Chemical structures of lead compounds in nalidixic acid series.
Molecules 26 04742 g009
Molecules 26 04742 g010 550
Figure 10. Percentage of inhibition of quinoxaline-incorporated Schiff bases against Mycobacterium tuberculosis.
Figure 10. Percentage of inhibition of quinoxaline-incorporated Schiff bases against Mycobacterium tuberculosis.
Molecules 26 04742 g010
Molecules 26 04742 g011 550
Figure 11. Structure of the lead compound 3-((4-methoxybenzyl)amino)-6-(trifluoromethyl)quinoxaline-2-carboxylic acid, a new DprE1 inhibitor.
Figure 11. Structure of the lead compound 3-((4-methoxybenzyl)amino)-6-(trifluoromethyl)quinoxaline-2-carboxylic acid, a new DprE1 inhibitor.
Molecules 26 04742 g011
Molecules 26 04742 g012 550
Figure 12. General structure of 1,2,3-triazole analogs of quinoxaline-1,4-di-N-oxide.
Figure 12. General structure of 1,2,3-triazole analogs of quinoxaline-1,4-di-N-oxide.
Molecules 26 04742 g012
Molecules 26 04742 g013 550
Figure 13. Design of 1,4-di-N-oxide quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives.
Figure 13. Design of 1,4-di-N-oxide quinoxaline-2-ylmethylene isonicotinic acid hydrazide derivatives.
Molecules 26 04742 g013
Molecules 26 04742 g014 550
Figure 14. Design of the quinoxaline 1,4-di-N-oxide derivatives.
Figure 14. Design of the quinoxaline 1,4-di-N-oxide derivatives.
Molecules 26 04742 g014
Table
Table 1. Data sources and searches.
Table 1. Data sources and searches.
SiteKeyword 1Boolean OperatorKeyword 2DateFilter
MEDLINE/PubMed (National Library of Medicine—www.ncbi.nlm.nih.gov/pubmed (accessed on 13 April 2021)QuinoxalineANDTuberculosis01 January 2011–01 April 2021Document type: journal articles
Web of Science (Thomson Reuters Scientific—www.webofknowledge.com (accessed on 13 April 2021)Quinoxaline (topic)ANDTuberculosis (Topic)2011–2021Document type: only articles
Science Direct Elsevier (www.sciencedirect.com (accessed on 13 April 2021)QuinoxalineANDTuberculosis2011–2021Document type: only research articles
Table
Table 2. Inclusion and exclusion criteria.
Table 2. Inclusion and exclusion criteria.
ParameterInclusionExclusion
1LanguageFrench, EnglishAny other language
2Type of studyIn vitro and/or in vivo studies, biological activityArticles that focus only on synthesis or other purely chemical parameters
3Type of publicationOriginal manuscriptsBook chapters, posters, reviews
4Search terms Merely citing keywords in the text
Table
Table 3. Chemical structure, minimal inhibitory concentration (MIC) values against Mycobacterium tuberculosis [30,31,32].
Table 3. Chemical structure, minimal inhibitory concentration (MIC) values against Mycobacterium tuberculosis [30,31,32].
CompoundStructureMIC (µg/mL)
2 Molecules 26 04742 i00150
3 Molecules 26 04742 i00212.5
4 Molecules 26 04742 i00325
5 Molecules 26 04742 i00412.5
6 Molecules 26 04742 i00525
Rifampicin–0.25
Isoniazid–0.20
Table
Table 4. Chemical structure and MIC values against Mycobacterium tuberculosis of the best candidates from pyrrolo[1,2-a]quinoxaline series.
Table 4. Chemical structure and MIC values against Mycobacterium tuberculosis of the best candidates from pyrrolo[1,2-a]quinoxaline series.
CompoundStructureMIC (µg/mL)
7 Molecules 26 04742 i0065
8 Molecules 26 04742 i0075
9 Molecules 26 04742 i0085
10 Molecules 26 04742 i0095
Table
Table 5. Chemical structure of some quinoxalinyl chalcones and their MIC values against Mycobacterium tuberculosis.
Table 5. Chemical structure of some quinoxalinyl chalcones and their MIC values against Mycobacterium tuberculosis.
CompoundStructureMIC (µg/mL)
14 Molecules 26 04742 i0103.12
15 Molecules 26 04742 i0113.12
16 Molecules 26 04742 i01250
17 Molecules 26 04742 i01325
18 Molecules 26 04742 i01425
Streptomycin 6.25
Ciprofloxacin 3.12
Pyrazinamide 3.12
Table
Table 6. MIC values against Mycobacterium tuberculosis of quinoxaline-derived chalcones.
Table 6. MIC values against Mycobacterium tuberculosis of quinoxaline-derived chalcones.
CompoundStructureMIC (µg/mL)
19 Molecules 26 04742 i01512.5
20 Molecules 26 04742 i0163.13
21 Molecules 26 04742 i01712.5
22 Molecules 26 04742 i0186.25
23 Molecules 26 04742 i01912.5
24 Molecules 26 04742 i0205
Rifampicin <0.2
Moxifloxacin <0.2
Isoniazid 0.39
Table
Table 7. Chemical structure of some spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids and their MIC values against Mycobacterium tuberculosis.
Table 7. Chemical structure of some spiropyrrolidine tethered indenoquinoxaline heterocyclic hybrids and their MIC values against Mycobacterium tuberculosis.
CompoundStructureMIC (µg/mL)
28 Molecules 26 04742 i0213.125
29 Molecules 26 04742 i0226.25
30 Molecules 26 04742 i02312.5
31 Molecules 26 04742 i0241.56
Ethambutol 1.56
Rifampicin 0.1
Isoniazid 0.05
Table
Table 8. Chemical structure and MIC values against Mycobacterium tuberculosis of the best candidates from the quinoxaline alkynyl series.
Table 8. Chemical structure and MIC values against Mycobacterium tuberculosis of the best candidates from the quinoxaline alkynyl series.
CompoundStructureMIC90 (µM)
32 Molecules 26 04742 i0254.26
33 Molecules 26 04742 i0264.55
34 Molecules 26 04742 i0271.13
35 Molecules 26 04742 i0286.47
36 Molecules 26 04742 i0291.59
37 Molecules 26 04742 i0301.80
38 Molecules 26 04742 i0312.74
Rifampicin 0.01
Table
Table 9. Antimycobacterial activity of quinoxaline derivatives based on molecular hybridization of quinoxaline 1,4-di-N-oxide with the chalcone and fluoroquinolone scaffolds.
Table 9. Antimycobacterial activity of quinoxaline derivatives based on molecular hybridization of quinoxaline 1,4-di-N-oxide with the chalcone and fluoroquinolone scaffolds.
CompoundStructureMIC (µM)
40 Molecules 26 04742 i0323.1
41 Molecules 26 04742 i0333.1
42 Molecules 26 04742 i0341.6
43 Molecules 26 04742 i0351.6
44 Molecules 26 04742 i0363.1
Ethambutol 6.2
Rifampicin 0.3
Isoniazid 0.04
Table
Table 10. Antimycobacterial activity of quinoxaline derivatives based on molecular hybridization of quinoxaline 1,4-di-N-oxide with the thiazolidinone scaffold.
Table 10. Antimycobacterial activity of quinoxaline derivatives based on molecular hybridization of quinoxaline 1,4-di-N-oxide with the thiazolidinone scaffold.
CompoundStructureMIC (µg/mL)
45 Molecules 26 04742 i0371.56
46 Molecules 26 04742 i0381.56
47 Molecules 26 04742 i0391.56
48 Molecules 26 04742 i0401.56
Rifampicin 0.125
Table
Table 11. Chemical structure of some quinoxaline-1,4-di-N-oxide derivatives variously substituted at the C2 position and their MIC values against Mycobacterium tuberculosis.
Table 11. Chemical structure of some quinoxaline-1,4-di-N-oxide derivatives variously substituted at the C2 position and their MIC values against Mycobacterium tuberculosis.
CompoundStructureMIC (µg/mL)
57 Molecules 26 04742 i0411.56
58 Molecules 26 04742 i0420.78
59 Molecules 26 04742 i0430.39
60 Molecules 26 04742 i0440.78
61 Molecules 26 04742 i0450.39
62 Molecules 26 04742 i0461.56
Isoniazid 0.2
Table
Table 12. Chemical structure on methyl, ethyl, isopropyl, and n-propyl esters of quinoxaline 1,4-di-N-oxide series and their MIC values against Mycobacterium tuberculosis.
Table 12. Chemical structure on methyl, ethyl, isopropyl, and n-propyl esters of quinoxaline 1,4-di-N-oxide series and their MIC values against Mycobacterium tuberculosis.
CompoundStructureMicroplate Alamar Blue Assay MIC (µg/mL)
63 Molecules 26 04742 i0470.14
64 Molecules 26 04742 i0480.10
65 Molecules 26 04742 i0490.15
66 Molecules 26 04742 i0500.08
67 Molecules 26 04742 i0510.14
68 Molecules 26 04742 i0520.15
69 Molecules 26 04742 i0530.13
70 Molecules 26 04742 i0540.14
Isoniazid 0.12
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Montana, M.; Montero, V.; Khoumeri, O.; Vanelle, P. Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis. Molecules 2021, 26, 4742. https://doi.org/10.3390/molecules26164742

AMA Style

Montana M, Montero V, Khoumeri O, Vanelle P. Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis. Molecules. 2021; 26(16):4742. https://doi.org/10.3390/molecules26164742

Chicago/Turabian Style

Montana, Marc, Vincent Montero, Omar Khoumeri, and Patrice Vanelle. 2021. "Quinoxaline Moiety: A Potential Scaffold against Mycobacterium tuberculosis" Molecules 26, no. 16: 4742. https://doi.org/10.3390/molecules26164742

Article Metrics

Back to TopTop